Brian Burgess, DO, PhD, a first-year fellow at the University of Kentucky, discusses the biggest challenge with targeted therapies in ovarian cancer. PARP resistance has become a huge barrier in this treatment paradigm.
Brian Burgess, DO, PhD, a first-year fellow at the University of Kentucky, discusses the biggest challenge with targeted therapies in ovarian cancer. PARP resistance has become a huge barrier in this treatment paradigm.
While the drugs in this field are very potent, chemotherapy resistance presents itself as a major challenge when treating patients with ovarian cancer. Burgess says that researchers believed targeted therapies would help overcome such barriers, but chemotherapy resistance becomes an issue primarily in long-term treatment.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More